

Thursday, October 01, 2009

Wednesday April 28, 2010

9:00- 9:15 Welcome

Dr. JC Acevedo, Dr. Kent C. Osborne

Plenary conference:

9:15 – 9:45 Do we have to perform genetic screening to every high risk woman?

Judith Garber, MD

9:15- 12:30 Risk and Risk Prevention for breast cancer module

9:35 – 9:55 Breast imaging: Magnetic resonance, mammography and ultrasound for the surveillance in high risk population women.

9:15 – 9:35 Risk for breast cancer classification and its management in high risk
Judith Garber, MD

10:45 -11:05 Management of patients with high histological risk
O. Peralta, MD

9:55 – 10:15 Management of patients with BRCA 1 or 2 breast cancer
Including contra-lateral breast cancer
Judith Garber, MD

10:15 -10:45 Coffee break

11:05 – 11:25 Medical and surgical prevention for high risk breast and ovarian cancer women
Judith Garber, MD

11:25 – 11:35 Pre-malignant lesions prevalence in high risk women treated with prophylactic bilateral mastectomy
A. Ibarra, MD

11:45 - 12:05 Psychological counseling for high risk patient and her family
Veronica Roberts, Ps

Lunch and Industry Symposium

14:30 – 17:30

Imaging in breast cancer module

14:30–15:00 **Plenary Conference**

Breast Cancer Screening: Benefits and Controversies

15:00 – 15:20 Magnetic resonance imaging-guided biopsy

15:20 - 15:40 Imaging the tumor in women undergoing neo-adjuvant therapy

15:40 – 16:10 Coffee break

16:10 – 16:30 Future of the breast imaging: MRI and spectroscopy, nano-technology, diffusion.

16:30 – 17:30 Clinical cases discussion

Radiologist, pathologist, surgeon, radiotherapist and oncologist

17:30 – 18:30

MRI in Local Extension Evaluation Controversy The impact of breast MRI on surgical decision-making: Are patients at risk for mastectomy?

17:30 – 17:50 The radiologist point of view USA radiologist

17:50 – 18:10 The clinician point of view
M. Morrow, MD

18:10 – 18:30 Q & A

18:30 – 19:30 Satellite Symposium Jorge Gomez, MD and the USA-Latin American Cancer Network

19:30 Welcome Reception

Thursday April 29, 2010

9:00 – 9:30 Plenary Conference: Diagnostic and prognostic markers for breast cancer Dra. Tavassoli

9:30 – 9:50 Minimal residual disease and its significance for breast cancer therapy Dr. Luis Cereceda

9:50 – 10:10 Micro and macro environment in breast cancer Dra Tavassoli

10:10 – 10:30 Tamoxifen and endometrium Dr. Luis Contreras

10:30 – 11:00 Coffee break

11:00 – 11:20 Ductal intra-epithelial neoplasm's: Morphology, associated risk and molecular disturbances Dra Tavassoli

11:20 -12:00 Standardization for c-erb-B-2 assessment: Immuno- histochemistry , CISH, FISH Dr. Luis Contreras

12:00 – 12:20 Cytological assessment of surgical margins in breast pathology and sentinel lymph node. Dr. Álvaro Ibarra

Lunch and Industry Symposium

Thursday afternoon

14:30 – 15:00 Plenary Conference:

Clinical and pathological issues in basal-like breast cancer.

Mini Symposium: Taking care of the patient with triple negative disease

15:00 – 15:20 Molecular profile of triple negative patient (DNA, RNA and proteins)

15:20 – 16:10 Which is the best adjuvant therapy and its sequence?

16:10 – 16:40 Coffee break

16:40 – 17:00 Triple negative metastatic patient: How do we proceed after anthracyclines and taxanes

17:00 – 17:20 Molecular therapies for triple negative disease:
Edith Perez MD.

17:20 – 17:50 Plenary Conference:

The role of surgery in the metastatic breast cancer: the primary breast tumor and solitary metastases

M. Morrow, MD

18:00 - 19:00 Industry Symposium

Friday April 30, 2010

9:00 – 9:30 Plenary Conference:

Are we ready for personalized adjuvant breast cancer treatment?

Oncotype-DX, Mammoprint, Rotterdam.

C Kent Osborne MD.

Mini Symposium:

Up-date on treatment on ER and HER 2 positive breast cancer

9:30 – 9:50 Is there still a role for adjuvant chemotherapy in postmenopausal patients?

9:50 - 10:05 Is there still a role for tamoxifen in the adjuvant treatment of postmenopausal patients?

10:05 - 10:35 Coffee Break

10:35 - 10:55 Role of HER-2 inhibitors in the adjuvant setting

10:55 – 11:15 Role of HER-2 inhibitors in the metastatic setting.

11:15 – 11:35 Endocrine adjuvant treatment in the pre-menopausal patient: Role of ovarian ablation/suppression.

11:35 – 12:00 Dual inhibition: use of growth factor inhibitors and endocrine blockade: Ready for clinical use?

C. Kent Osborne MD.

Lunch and Industry Symposium

14:30 – 15:00 Plenary Conference:

Breast onco-plastic surgery: Past, present and future

Dr. E . González

Mini Symposium

Onco- plastic surgery and breast reconstruction

15:00-15:15 Immediate breast reconstruction

Dra. Nubia Aliaga

15:15 – 15:30 Breast reconstruction using expanders and prosthesis

Dr. H. Paredes

15:30 – 15:50 Indications guide for breast reconstruction after breast previous or adjuvant radiotherapy

Dr. A Rancati

15:50 -16:10 Technical Videos

- Skin sparing mastectomy, sentinel lymph node and immediate breast reconstruction with expanders
Dr. E. González
- Skin sparing mastectomy, axillary clearance and immediate reconstruction with microsurgical TRAM
Dr .E. González
- Deferred breast reconstruction with dorsal width and definitive expander
Dr. E. González

16:10 - 16:30 Round table

Chair: Dr. Hernando Paredes

Panelists: Dra. N. Aliaga, Dr. E. González, A. Rancati

16:30 - 16:50 Coffee break

16:50 - 17:00 Partial mastectomy and its repair with local flaps: Indications and techniques

Dr. A. Rancati

17:00 - 17:20 Breast reconstruction with flaps

Dr. Hernando Paredes

17:20 - 17:40 Research on and clinical use of stem cells and growth factors for the repair of sequelae from surgical breast cancer treatment

Dr. A. Rancati

Surgical techniques videos

17:40 - 18:00

- Lipofiling and conservative treatment of breast cancer

Dr. A. Rancati

- Breast reduction and conservative treatment of breast cancer

Dr. A. Rancati

17:20 - 17:40

Mastectomías con conservación de piel y reconstrucción mamaria inmediata

Dr. O. Bernabó

18:00 – 18:15

Video discussion

18:15 Adjourn